MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ATHA had $986K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$986K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Total operating expenses
23,701 -
Loss from operations
-23,701 -
Other income, net
981 -
Net loss
-6,611 -16,109
Stock-based compensation
1,410 3,234
Depreciation expense
243 486
Non-cash lease expense
69 132
Amortization of premiums and accretion of discounts on available-for-sale securities, net
70 192
Prepaid expenses and other current and long-term assets, net
-603 -1,164
Accounts payable and accrued liabilities
-207 -10,179
Operating lease liability
-105 -200
Net cash used in operating activities
-4,668 -21,664
Purchases of available-for-sale securities
3,336 16,269
Maturities of available-for-sale securities
8,990 9,359
Net cash (used in) provided by investing activities
5,654 -6,910
Proceeds from issuance of common stock under employee stock purchase plan
0 24
Net cash provided by financing activities
0 24
Net decrease in cash, cash equivalents and restricted cash
986 -28,550
Cash and cash equivalents at beginning of period
49,069 -
Cash and cash equivalents at end of period
21,505 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Athira Pharma, Inc. (ATHA)

Athira Pharma, Inc. (ATHA)